N-terminal truncation of cardiac troponin subunits and their roles in cardiovascular disease
Methods for diagnosing, determining the likelihood of developing cardiac disease by measuring the level of a truncated form of cardiac Troponin T are provided. Also provided are methods for preventing treating or ameliorating a symptom associated with cardiac disease by administering a therapeutically effective amount of a modulator of the posttranslational production of N-terminally truncated forms of cardiac troponin T.
1. A method of determining the likelihood of developing or diagnosing a cardiac disease comprising
(a) obtaining a biological sample of a body fluid from a mammalian subject;
(b) measuring the level of at least one truncated form of cardiac troponin T in said sample; and
(c) determining the likelihood of developing or diagnosing a cardiac disease based on the measured level of at least one truncated form of cardiac troponin T in said sample.
2. A method of determining the likelihood of developing or diagnosing a cardiac disease comprising
(a) obtaining a biological sample of a body fluid from a subject;
(b) measuring the level of at least one truncated form of cardiac troponin T in the sample resulting from a post-translational truncation of cardiac troponin T; and
(c) determining the likelihood of developing or diagnosing a cardiac disease based on the measured level of at least one truncated form of cardiac troponin T in the sample.
3. A method of determining the likelihood of developing or diagnosing a cardiac disease comprising
(a) obtaining a biological sample of a body fluid from a subject;
(b) measuring the level of at least one truncated form of cardiac troponin T in the sample resulting from a proteolytic truncation of cardiac troponin T; and
(c) determining the likelihood of developing or diagnosing a cardiac disease based on the measured level of at least one truncated form of cardiac troponin T in the sample.
4. A method of determining the likelihood of developing or diagnosing a cardiac disease comprising
(a) obtaining a biological sample of a body fluid from a subject;
(b) measuring the level of at least one truncated form of cardiac troponin T in the sample resulting from NH 2 -terminal truncation of cardiac troponin T; and
(c) determining the likelihood of developing or diagnosing a cardiac disease based on the measured level of at least one truncated form of cardiac troponin T in the sample.
5. The method according to claim 1 , 2 , 3 or 4 wherein the subject is a human patient.
6. The method according to claim 1 , 2 , 3 or 4 wherein the truncated form of cardiac troponin T is cTnT 72-291 .
7. The method according to claim 1 , 2 , 3 or 4 wherein said measuring comprises an immunoassay.
8. The method according to claim 7 wherein said immunoassay comprises an antibody selectively binding to said truncated form of cardiac troponin T.
9. The method according to claim 8 wherein said truncated form of cardiac troponin T is cTnT 72-291 .
10. The method according to claim 7 wherein said immunoassay comprises a differential measurement of a truncated cTnT based on measures of the levels of at least two forms of cTnT in said sample.
11. The method according to claim 10 wherein the differential measurement comprises detecting antibody binding and assessing cTnT size.
12. The method according to claim 11 wherein said differential measurement comprises a comparison of the measured quantities of a truncated cTnT and a full-length cTnT.
13. The method according to claim 1 , 2 , 3 , or 4 wherein the truncated form of cardiac troponin T consists of an NH 2 -terminal peptide of cTnT.
14. The method according to claim 1 , 2 , 3 or 4 wherein the truncated form of cardiac troponin T is cTnT 1-71 .
15. The method according to claim 1 , 2 , 3 , or 4 wherein the truncated form of cardiac troponin T consists of NH 2 -terminal truncated cTnT.